D. E. Shaw & Co., Inc. Taysha Gene Therapies, Inc. Transaction History

D. E. Shaw & Co., Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.76 - $4.94 $48,067 - $134,916	-27,311 Reduced 20.29%	107,274 $207,000
Q2 2022 Aug 15, 2022	BUY	$2.47 - $6.77 $147,831 - $405,191	59,851 Added 80.09%	134,585 $501,000
Q1 2022 May 16, 2022	BUY	$5.22 - $11.86 $390,111 - $886,345	74,734 New	74,734 $487,000
Q3 2021 Nov 15, 2021	SELL	$15.82 - $21.57 $181,107 - $246,933	-11,448 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$19.29 - $26.38 $220,831 - $301,998	11,448 New	11,448 $243,000

119

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $119M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.